If software promises to save lives on the scale that drugs now can, big data may be expected to behave as big pharma has done.
如果软件在拯救生命方面可望达到药物的水平，那么大数据也可能会和大型制药公司一样行事。
If software promises to save lives on the scale that drugs now can, big data may be expected to behave as a big pharma has done.
如果软件能够像现在的药物一样拯救生命，那么大数据就有望像大型制药公司那样发挥作用。
Yet the clouds have darkened over Big Pharma.
然而大型制药公司的前景却已黯淡。
Big Pharma continues its march into emerging markets.
大型制药公司继续进军新兴市场。
Big Pharma typically powers their trials at no less than 80 percent.
大型医药企业通常将实验效强定在80%以上。
All of this is bad news for big pharma, but it opens the way for other approaches.
这一切对于大型医药公司来说是坏消息，但是却为别的途径打开了大门。
There are the endless digs at Wall Street and Big Pharma, not to mention the beating up of BP.
在华尔街和大药厂仍有无数个创伤，更别提英国石油公司的打击。
Big Pharma has long flirted with branded generics, but this time it looks like the real thing.
制药大亨们早就对品牌仿制药有意，但这次看起来像是要玩真的了。
Modern cancer care is big business, and cancer drugs are envisaged as the future cash cows of big Pharma.
现代癌症治疗是一个盘子很大的行业，抗癌症药物被认为是大型医药企业的摇钱树。
This promised pot of gold was designed to support small generics firms—but Big Pharma has found a loophole.
这个被允诺的优惠政策用于支持小型的学名药制药公司，但是大型制药公司发现了其中的一个漏洞。
With its traditional approach, Big Pharma is not coming up with new drugs fast enough to fill its emptying pipeline.
靠传统方法，大型制药公司无法及时推出新药以填补空缺的产品线。
Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech's upstarts.
打的制药商渴望能够再填充药物运输的空缺，就近几年来看，对生物化学的新型企业看上去比较有希望。
A good middle manager doesn't have to be a physician or former Big Pharma exec; he or she just needs clinical trial experience.
一个良好的中层管理人员没有必要在医学专业或有大公司的经验，他或她只需要有临床试验经验即可。
Unlike firms in other businesses, Big Pharma still does most things in-house, from research to manufacturing, sales and distribution.
与其他行业的公司不同，大型制药公司仍然将从研发到生产销售的大部分业务在公司内完成。
China is on the minds and lips of the CEO's of the large multi-national pharmaceutical companies, commonly referred to as Big pharma.
大型跨国制药公司也就是通常所说的制药巨头的CEO们时常想到或说起中国。
This will create more and different partnering opportunities as both Big Pharma and established biosimilars players create pipelines of compounds.
这会给大型制药公司和现有生物仿制药公司创造更多不同方式的合作机会。
Like Big Pharma, which introduced many "me too" drugs, device companies have sustained themselves by making small improvements to existing products.
像一些引进仿制药的大型制药公司，以及设备公司已经有很长一段时间没有对现有的产品做出改进。
The coming year will bring dramatic moves by Big Pharma to learn from, copy and even get into bed with the rivals it once decried as copycats and scofflaws.
明年大型药厂将有大的动作，包括向曾经被他们斥为盲目模仿者及屡屡违规者的竞争对手学习、模仿甚至成为合作伙伴。
But recently the big pharma company Pfizer has developed a new drug, tanezumab, that inhibits a protein involved in transmitting the pain signal to the brain.
但是最近著名的大型药企pfizer研制出了一种名为tanezumab的新药，这种药能抑制一种旨在传递痛觉信号的蛋白质发挥作用。
Big Pharma has already embraced branded generics abroad; the same principles apply here. Branded generics have the ability to change the US generics landscape.
制药大亨们已经接受了国外品牌仿制药；同样的法则在这里同样适用，品牌仿制药有能力改变美国仿制药格局。
Many detest Big Pharma, and are convinced that selling out to bureaucratic marketing machines will destroy the heart and soul of their smaller, more agile firms.
他们大都憎恨制药商，并坚信委身陈旧的营销模式会将小公司灵活精干的文化理念破坏殆尽。
Since these firms are strong in their field, they should be able to find new owners or partners with deep pockets, be they big pharma firms or private-equity investors.
因为这些公司在其自身的行业里还是很强大的，所以它们将来可以找到新的出资人或者合作伙伴，可能是大型制药公司或者私募投资者。
I do not like the hype and some other salesmanship of big pharma and bio-tech companies, but this industry has made enormous contributions to raising world health.
我不喜欢大型制药公司和生物技术公司的天花乱坠的广告以及其它五花八门的推销术，但是制药产业已经为提高世界健康水平作出了巨大的贡献。
Investors had sent Big Pharma a very clear message: Stop spending so much money to create new drugs, even if you're losing exclusivity on your older drugs through the so-called patent cliff.
投资者向医药巨头们传达了一个明确信息：不要再投入巨资用于新药研发，即便公司正在失去旧有药品的专利保护，面临所谓的专利悬崖困境。
The argument in defense of this system offered by Big Pharma is simple, and sounds reasonable at first: we need to charge large sums for "our" drugs so we can develop more life-saving medicines.
由各大医药公司提供的捍卫目前这种医药制度的论点很简单，而且乍听上去也挺合理：我们要为“我们的”药品定高额价格，这样我们才可以开发更多的救命药。
The argument in defense of this system offered by Big Pharma is simple, and sounds reasonable at first: we need to charge large sums for "our" drugs so we can develop more life-saving medicines.
由各大医药公司提供的捍卫目前这种医药制度的论点很简单，而且乍听上去也挺合理：我们要为“我们的”药品定高额价格，这样我们才可以开发更多的救命药。
应用推荐